<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620528</url>
  </required_header>
  <id_info>
    <org_study_id>M12-665</org_study_id>
    <nct_id>NCT01620528</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain</brief_title>
  <acronym>ELARIS EM-I</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized study evaluating the safety and efficacy of elagolix in the management of
      moderate to severe endometriosis-associated pain in adult premenopausal female participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, double-blind, placebo-controlled, randomized study to assess
      the safety and efficacy of two doses of elagolix versus placebo in premenopausal 18 to 49
      year old women with moderate to severe endometriosis-associated pain. The study consists of 4
      periods: 1) Washout Period (if applicable); 2) a Screening Period of up to 100 days prior to
      first dose; 3) a 6 month Treatment Period; and 4) a Post treatment Follow-up Period of up to
      12 months (if applicable). An electronic diary will be dispensed and training provided to
      record endometriosis-associated pain, uterine bleeding, and analgesic medication use for
      endometriosis-associated pain on a daily basis. Pregnancy testing will be performed monthly
      throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 22, 2012</start_date>
  <completion_date type="Actual">September 28, 2015</completion_date>
  <primary_completion_date type="Actual">November 14, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS)</measure>
    <time_frame>At Month 3 of the Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Responders at Month 3 Based on Daily Assessment of Non-Menstrual Pelvic Pain (NMPP)</measure>
    <time_frame>At Month 3 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in Numeric Rating Scale (NRS) Scores</measure>
    <time_frame>Baseline, Month 3 of the Treatment Period</time_frame>
    <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in DYS</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in NMPP</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in Analgesic Use Across Both Classes of Rescue Analgesics</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in Analgesic Use Across Both Classes of Rescue Analgesics</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in Dyspareunia (DYSP)</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The DYSP pain scale ranges from 0 (absent) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in Use of Narcotic Class of Medication (Opioids)</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>Permitted rescue narcotic analgesics included 5 mg hydrocodone + 300 or 325 mg acetaminophen and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 1 Based on Daily Assessment of DYS</measure>
    <time_frame>At Month 1 of the Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 2 Based on Daily Assessment of DYS</measure>
    <time_frame>At Month 2 of the Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 4 Based on Daily Assessment of DYS</measure>
    <time_frame>At Month 4 of the Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 5 Based on Daily Assessment of DYS</measure>
    <time_frame>At Month 5 of the Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 6 Based on Daily Assessment of DYS</measure>
    <time_frame>At Month 6 of the Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 1 Based on Daily Assessment of NMPP</measure>
    <time_frame>At Month 1 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 2 Based on Daily Assessment of NMPP</measure>
    <time_frame>At Month 2 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 4 Based on Daily Assessment of NMPP</measure>
    <time_frame>At Month 4 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 5 Based on Daily Assessment of NMPP</measure>
    <time_frame>At Month 5 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 6 Based on Daily Assessment of NMPP</measure>
    <time_frame>At Month 6 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 1 for DYSP</measure>
    <time_frame>At Month 1 of the Treatment Period</time_frame>
    <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 2 for DYSP</measure>
    <time_frame>At Month 2 of the Treatment Period</time_frame>
    <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 4 for DYSP</measure>
    <time_frame>At Month 4 of the Treatment Period</time_frame>
    <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 5 for DYSP</measure>
    <time_frame>At Month 5 of the Treatment Period</time_frame>
    <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders at Month 6 for DYSP</measure>
    <time_frame>At Month 6 of the Treatment Period</time_frame>
    <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in Mean Pain Score for DYS</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 2 in Mean Pain Score for DYS</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in Mean Pain Score for DYS</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 4 in Mean Pain Score for DYS</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 5 in Mean Pain Score for DYS</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 1 in Mean Pain Score for DYS</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 2 in Mean Pain Score for DYS</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 3 in Mean Pain Score for DYS</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 4 in Mean Pain Score for DYS</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 5 in Mean Pain Score for DYS</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 6 in Mean Pain Score for DYS</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in Mean Pain Score for NMPP</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 2 in Mean Pain Score for NMPP</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in Mean Pain Score for NMPP</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 4 in Mean Pain Score for NMPP</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 5 in Mean Pain Score for NMPP</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 1 in Mean Pain Score for NMPP</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 2 in Mean Pain Score for NMPP</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 3 in Mean Pain Score for NMPP</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 4 in Mean Pain Score for NMPP</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 5 in Mean Pain Score for NMPP</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 6 in Mean Pain Score for NMPP</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in Mean Pain Score of DYSP</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 2 in Mean Pain Score of DYSP</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 4 in Mean Pain Score of DYSP</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 5 in Mean Pain Score of DYSP</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in Mean Pain Score of DYSP</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in Analgesic Use Across Both Classes of Rescue Analgesics</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 2 in Analgesic Use Across Both Classes of Rescue Analgesics</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 4 in Analgesic Use Across Both Classes of Rescue Analgesics</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 5 in Analgesic Use Across Both Classes of Rescue Analgesics</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Patient Global Impression of Change (PGIC) at Month 1</measure>
    <time_frame>Month 1 of Treatment Period</time_frame>
    <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to PGIC at Month 2</measure>
    <time_frame>Month 2 of Treatment Period</time_frame>
    <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to PGIC at Month 3</measure>
    <time_frame>Month 3 of Treatment Period</time_frame>
    <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to PGIC at Month 4</measure>
    <time_frame>Month 4 of Treatment Period</time_frame>
    <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to PGIC at Month 5</measure>
    <time_frame>Month 5 of Treatment Period</time_frame>
    <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to PGIC at Month 6</measure>
    <time_frame>Month 6 of Treatment Period</time_frame>
    <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in NRS Scores</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 2 in NRS Scores</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 4 in NRS Scores</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 5 in NRS Scores</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in NRS Scores</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in the Pain Domain of the Endometriosis Health Profile-30 (EHP-30)</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in the Pain Domain of the EHP-30</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in the Pain Domain of the EHP-30</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domian is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in the Sexual Intercourse Domain of the EHP-30</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domian is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in the Sexual Intercourse Domain of the EHP-30</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in the Sexual Intercourse Domain of the EHP-30</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domian is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in Health Related Productivity Questionnaire (HRPQ): Number of Hours of Work Lost From Workplace Due to Absenteeism</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 2 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 4 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 5 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 1 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</measure>
    <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 2 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</measure>
    <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 3 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</measure>
    <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 4 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</measure>
    <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 5 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</measure>
    <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</measure>
    <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
    <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Endometriosis-Related Non-Study Health Visits During the Treatment Period</measure>
    <time_frame>Up to Month 6 of Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Hospitalization</measure>
    <time_frame>Up to Month 6 of Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Emergency Room/Outpatient Procedures During the Treatment Period, by Type</measure>
    <time_frame>Up to Month 6 of Treatment Period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">872</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Elagolix 150 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix 150 mg once daily (QD) for the 6-month Treatment Period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix 200 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID for the 6-month Treatment Period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elagolix</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Elagolix 150 mg QD</arm_group_label>
    <arm_group_label>Elagolix 200 mg BID</arm_group_label>
    <other_name>ABT-620, elagolix sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Premenopausal female, between 18 and 49 years of age, inclusive, at the time of
             signing consent.

          2. Clinical diagnosis of endometriosis (laparoscopy or laparotomy) performed within 10
             years of entry into Washout (if applicable) or Screening.

          3. Agrees to use required birth control methods during the entire length of participation
             in the study.

          4. Subject has a Composite Pelvic Signs and Symptoms Score total score of  6 at
             Screening with a score of at least 2 for dysmenorrhea AND at least 2 for non-menstrual
             pelvic pain. 5. Subjects must have at least two menstrual cycles 24 to 38 days within
             the Screening Period, prior to Day 1

        Exclusion Criteria:

          1. Subject is pregnant or breast feeding or is planning a pregnancy within the next 24
             months or is less than 6 months postpartum, post-abortion, or post-pregnancy at the
             time of entry into the Screening Period.

          2. Subject has a history of previous non-response to Gonadotropin-releasing hormone
             (GnRH) agonists, GnRH antagonists, Depot Medroxyprogesterone Acetate, or aromatase
             inhibitors as assessed by subject report of no improvement in dysmenorrhea or
             non-menstrual pelvic pain (subject report of partial response to or side effects from
             these agents is not exclusionary).

          3. Subject has chronic pelvic pain that is not caused by endometriosis that requires
             chronic analgesic or other chronic therapy, or that would interfere with the
             assessment of endometriosis related pain.

          4. Clinically significant gynecologic condition identified on Screening transvaginal
             ultrasound or endometrial biopsy.

          5. Subject has a history of osteoporosis or other metabolic bone disease.

          6. Subject has a current history of undiagnosed abnormal genital bleeding.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Duan, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med. 2017 Jul 6;377(1):28-40. doi: 10.1056/NEJMoa1700089. Epub 2017 May 19.</citation>
    <PMID>28525302</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>June 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <results_first_submitted>August 9, 2018</results_first_submitted>
  <results_first_submitted_qc>September 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2018</results_first_posted>
  <disposition_first_submitted>November 13, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>November 13, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 10, 2015</disposition_first_posted>
  <last_update_submitted>September 14, 2018</last_update_submitted>
  <last_update_submitted_qc>September 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gonadotropin-Releasing Hormone Antagonist</keyword>
  <keyword>Endometriosis associated pain</keyword>
  <keyword>Dysmenorrhea (DYS)</keyword>
  <keyword>Non-Menstrual Pelvic Pain (NMPP)</keyword>
  <keyword>Elagolix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>After completing the Treatment Period, participants (who were eligible and provided consent) entered a separate continuous-use extension study (Study M12-667, NCT01760954).</recruitment_details>
      <pre_assignment_details>Participants who prematurely discontinued from study drug and those who declined to participate in or who did not qualify for the continuous-use extension study, except for those who became pregnant, could elect to enter the Post-Treatment Follow-Up (PTFU) Period within this study for up to 12 additional months.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo twice daily (BID) for the 6-month Treatment Period</description>
        </group>
        <group group_id="P2">
          <title>Elagolix 150 mg QD</title>
          <description>Elagolix 150 mg once daily (QD) for the 6-month Treatment Period</description>
        </group>
        <group group_id="P3">
          <title>Elagolix 200 mg BID</title>
          <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="374"/>
                <participants group_id="P2" count="249"/>
                <participants group_id="P3" count="249">1 subject did not receive study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did Not Receive Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Noncompliant</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery/Invasive Intervention</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusionary Medication Received</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-Treatment Follow-Up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68">elected to enter the PTFU Period</participants>
                <participants group_id="P2" count="48">elected to enter the PTFU Period</participants>
                <participants group_id="P3" count="51">elected to enter the PTFU Period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed PTFU Month 6</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="26">Met criteria (reported a post-treatment menses, met the DXA criteria, and had a PTFU Month 6 visit).</participants>
                <participants group_id="P3" count="18">Met criteria (reported a post-treatment menses, met the DXA criteria, and had a PTFU Month 6 visit).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed PTFU Month 12</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exclusionary Medication Received</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery/Invasive Intervention</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least 1 dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo BID for the 6-month Treatment Period</description>
        </group>
        <group group_id="B2">
          <title>Elagolix 150 mg QD</title>
          <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
        </group>
        <group group_id="B3">
          <title>Elagolix 200 mg BID</title>
          <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="374"/>
            <count group_id="B2" value="249"/>
            <count group_id="B3" value="248"/>
            <count group_id="B4" value="871"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="6.35"/>
                    <measurement group_id="B2" value="31.5" spread="5.99"/>
                    <measurement group_id="B3" value="31.2" spread="6.33"/>
                    <measurement group_id="B4" value="31.5" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="374"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="248"/>
                    <measurement group_id="B4" value="871"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS)</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 3 of the Treatment Period</time_frame>
        <population>The modified intent-to-treat (mITT) analysis set; all randomized participants who took at least 1 dose of randomized, double-blind study drug. Population included mITT participants who either had data during the Month 3 35-day window or who prematurely discontinued prior to or at Month 3 and met the rules for last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS)</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The modified intent-to-treat (mITT) analysis set; all randomized participants who took at least 1 dose of randomized, double-blind study drug. Population included mITT participants who either had data during the Month 3 35-day window or who prematurely discontinued prior to or at Month 3 and met the rules for last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="46.4"/>
                    <measurement group_id="O3" value="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Responders at Month 3 Based on Daily Assessment of Non-Menstrual Pelvic Pain (NMPP)</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set; all randomized participants who took at least 1 dose of randomized, double-blind study drug. Population included mITT participants who either had data during the Month 3 35-day window or who prematurely discontinued prior to or at Month 3 and met the rules for last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 3 Based on Daily Assessment of Non-Menstrual Pelvic Pain (NMPP)</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set; all randomized participants who took at least 1 dose of randomized, double-blind study drug. Population included mITT participants who either had data during the Month 3 35-day window or who prematurely discontinued prior to or at Month 3 and met the rules for last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5"/>
                    <measurement group_id="O2" value="50.4"/>
                    <measurement group_id="O3" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in Numeric Rating Scale (NRS) Scores</title>
        <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
        <time_frame>Baseline, Month 3 of the Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in Numeric Rating Scale (NRS) Scores</title>
          <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="0.098"/>
                    <measurement group_id="O2" value="-1.74" spread="0.120"/>
                    <measurement group_id="O3" value="-2.39" spread="0.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 1 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Mean Change</param_type>
            <param_value>-0.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.155</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 1 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Mean Change</param_type>
            <param_value>-1.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.156</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.047"/>
                    <measurement group_id="O2" value="-0.89" spread="0.057"/>
                    <measurement group_id="O3" value="-1.75" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 2 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Mean Change</param_type>
            <param_value>-0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.074</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 2 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-1.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.076</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="0.035"/>
                    <measurement group_id="O2" value="-0.48" spread="0.043"/>
                    <measurement group_id="O3" value="-0.72" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 3 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Mean Change</param_type>
            <param_value>-0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 3 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
        <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
          <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>pills</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.032"/>
                    <measurement group_id="O2" value="-0.29" spread="0.039"/>
                    <measurement group_id="O3" value="-0.55" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 4 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.910</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Mean Change</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.051</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 4 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Mean Change</param_type>
            <param_value>-0.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.051</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
        <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
          <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>pills</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.036"/>
                    <measurement group_id="O2" value="-0.35" spread="0.043"/>
                    <measurement group_id="O3" value="-0.56" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 5 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.185</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Mean Change</param_type>
            <param_value>-0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 5 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in Dyspareunia (DYSP)</title>
        <description>The DYSP pain scale ranges from 0 (absent) to 3 (severe).</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in Dyspareunia (DYSP)</title>
          <description>The DYSP pain scale ranges from 0 (absent) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.041"/>
                    <measurement group_id="O2" value="-0.39" spread="0.050"/>
                    <measurement group_id="O3" value="-0.49" spread="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 6 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.144</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Mean Change</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 6 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Mean Change</param_type>
            <param_value>-0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.067</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in Use of Narcotic Class of Medication (Opioids)</title>
        <description>Permitted rescue narcotic analgesics included 5 mg hydrocodone + 300 or 325 mg acetaminophen and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in Use of Narcotic Class of Medication (Opioids)</title>
          <description>Permitted rescue narcotic analgesics included 5 mg hydrocodone + 300 or 325 mg acetaminophen and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>pills</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.024"/>
                    <measurement group_id="O2" value="-0.07" spread="0.029"/>
                    <measurement group_id="O3" value="-0.22" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 7 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.424</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Mean Change</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Ranked secondary efficacy endpoint 7 of 7.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Mean Change</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 1 Based on Daily Assessment of DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 1 of the Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 1 Based on Daily Assessment of DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="35.1"/>
                    <measurement group_id="O3" value="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 2 Based on Daily Assessment of DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 2 of the Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 2 Based on Daily Assessment of DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="44.8"/>
                    <measurement group_id="O3" value="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 4 Based on Daily Assessment of DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 4 of the Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 4 Based on Daily Assessment of DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7"/>
                    <measurement group_id="O2" value="47.6"/>
                    <measurement group_id="O3" value="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 5 Based on Daily Assessment of DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 5 of the Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward..</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 5 Based on Daily Assessment of DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward..</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="45.7"/>
                    <measurement group_id="O3" value="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 6 Based on Daily Assessment of DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 6 of the Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 6 Based on Daily Assessment of DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="42.1"/>
                    <measurement group_id="O3" value="75.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 1 Based on Daily Assessment of NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 1 Based on Daily Assessment of NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="32.3"/>
                    <measurement group_id="O3" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.103</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 2 Based on Daily Assessment of NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 2 Based on Daily Assessment of NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2"/>
                    <measurement group_id="O2" value="41.1"/>
                    <measurement group_id="O3" value="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 4 Based on Daily Assessment of NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 4 Based on Daily Assessment of NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4"/>
                    <measurement group_id="O2" value="53.2"/>
                    <measurement group_id="O3" value="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 5 Based on Daily Assessment of NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 5 Based on Daily Assessment of NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3"/>
                    <measurement group_id="O2" value="49.8"/>
                    <measurement group_id="O3" value="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 6 Based on Daily Assessment of NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 6 Based on Daily Assessment of NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="45.7"/>
                    <measurement group_id="O3" value="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 1 for DYSP</title>
        <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 1 of the Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 1 for DYSP</title>
          <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                    <measurement group_id="O2" value="30.4"/>
                    <measurement group_id="O3" value="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.306</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.239</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 2 for DYSP</title>
        <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 2 of the Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 2 for DYSP</title>
          <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1"/>
                    <measurement group_id="O2" value="33.7"/>
                    <measurement group_id="O3" value="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.855</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 4 for DYSP</title>
        <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 4 of the Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 4 for DYSP</title>
          <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1"/>
                    <measurement group_id="O2" value="44.3"/>
                    <measurement group_id="O3" value="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 5 for DYSP</title>
        <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 5 of the Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 5 for DYSP</title>
          <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3"/>
                    <measurement group_id="O2" value="43.7"/>
                    <measurement group_id="O3" value="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.061</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders at Month 6 for DYSP</title>
        <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
        <time_frame>At Month 6 of the Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders at Month 6 for DYSP</title>
          <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe). The criteria for a responder was based on a pre-defined threshold and accounted for analgesic use.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="39.6"/>
                    <measurement group_id="O3" value="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.126</p_value>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in Mean Pain Score for DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in Mean Pain Score for DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.044"/>
                    <measurement group_id="O2" value="-0.83" spread="0.054"/>
                    <measurement group_id="O3" value="-0.98" spread="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.070</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.070</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 2 in Mean Pain Score for DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 2 in Mean Pain Score for DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.042"/>
                    <measurement group_id="O2" value="-0.96" spread="0.052"/>
                    <measurement group_id="O3" value="-1.68" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.067</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.79</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.51</ci_lower_limit>
            <ci_upper_limit>-1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in Mean Pain Score for DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in Mean Pain Score for DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.043"/>
                    <measurement group_id="O2" value="-1.03" spread="0.052"/>
                    <measurement group_id="O3" value="-1.73" spread="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.069</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.54</ci_lower_limit>
            <ci_upper_limit>-1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 4 in Mean Pain Score for DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in Mean Pain Score for DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.045"/>
                    <measurement group_id="O2" value="-1.05" spread="0.054"/>
                    <measurement group_id="O3" value="-1.72" spread="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.071</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.072</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>-1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 5 in Mean Pain Score for DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 5 in Mean Pain Score for DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.045"/>
                    <measurement group_id="O2" value="-1.02" spread="0.054"/>
                    <measurement group_id="O3" value="-1.84" spread="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.071</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>-0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.072</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.58</ci_lower_limit>
            <ci_upper_limit>-1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 1 in Mean Pain Score for DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 1 in Mean Pain Score for DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.35" spread="2.079"/>
                    <measurement group_id="O2" value="-38.42" spread="2.547"/>
                    <measurement group_id="O3" value="-45.35" spread="2.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-24.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.288</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.45</ci_lower_limit>
            <ci_upper_limit>-16.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-31.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.299</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.41</ci_lower_limit>
            <ci_upper_limit>-23.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 2 in Mean Pain Score for DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 2 in Mean Pain Score for DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.44" spread="1.965"/>
                    <measurement group_id="O2" value="-44.23" spread="2.407"/>
                    <measurement group_id="O3" value="-77.22" spread="2.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>-30.79</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-30.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.107</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.77</ci_lower_limit>
            <ci_upper_limit>-23.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-63.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.148</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-70.85</ci_lower_limit>
            <ci_upper_limit>-56.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 3 in Mean Pain Score for DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 3 in Mean Pain Score for DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.80" spread="2.022"/>
                    <measurement group_id="O2" value="-47.01" spread="2.451"/>
                    <measurement group_id="O3" value="-79.74" spread="2.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-32.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.177</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.35</ci_lower_limit>
            <ci_upper_limit>-25.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-64.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.230</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.19</ci_lower_limit>
            <ci_upper_limit>-57.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 4 in Mean Pain Score for DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 4 in Mean Pain Score for DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.08" spread="2.088"/>
                    <measurement group_id="O2" value="-48.02" spread="2.519"/>
                    <measurement group_id="O3" value="-79.98" spread="2.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-29.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.272</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.28</ci_lower_limit>
            <ci_upper_limit>-22.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-61.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.356</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-69.44</ci_lower_limit>
            <ci_upper_limit>-54.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 5 in Mean Pain Score for DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 5 in Mean Pain Score for DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.09" spread="2.072"/>
                    <measurement group_id="O2" value="-46.72" spread="2.517"/>
                    <measurement group_id="O3" value="-84.58" spread="2.595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-28.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.260</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.96</ci_lower_limit>
            <ci_upper_limit>-21.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-66.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.321</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.95</ci_lower_limit>
            <ci_upper_limit>-59.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 6 in Mean Pain Score for DYS</title>
        <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 6 in Mean Pain Score for DYS</title>
          <description>The DYS pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.21" spread="2.217"/>
                    <measurement group_id="O2" value="-40.60" spread="2.681"/>
                    <measurement group_id="O3" value="-79.99" spread="2.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-21.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.479</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.20</ci_lower_limit>
            <ci_upper_limit>-13.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-60.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.557</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.77</ci_lower_limit>
            <ci_upper_limit>-52.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in Mean Pain Score for NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in Mean Pain Score for NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.023"/>
                    <measurement group_id="O2" value="-0.22" spread="0.028"/>
                    <measurement group_id="O3" value="-0.26" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 2 in Mean Pain Score for NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 2 in Mean Pain Score for NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.028"/>
                    <measurement group_id="O2" value="-0.33" spread="0.035"/>
                    <measurement group_id="O3" value="-0.44" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in Mean Pain Score for NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in Mean Pain Score for NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.032"/>
                    <measurement group_id="O2" value="-0.44" spread="0.039"/>
                    <measurement group_id="O3" value="-0.61" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 4 in Mean Pain Score for NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in Mean Pain Score for NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.034"/>
                    <measurement group_id="O2" value="-0.51" spread="0.041"/>
                    <measurement group_id="O3" value="-0.72" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 5 in Mean Pain Score for NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 5 in Mean Pain Score for NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.034"/>
                    <measurement group_id="O2" value="-0.49" spread="0.041"/>
                    <measurement group_id="O3" value="-0.74" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 1 in Mean Pain Score for NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 1 in Mean Pain Score for NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.51" spread="1.736"/>
                    <measurement group_id="O2" value="-13.74" spread="2.131"/>
                    <measurement group_id="O3" value="-15.23" spread="2.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-6.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.748</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.40</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-7.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.756</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.90</ci_lower_limit>
            <ci_upper_limit>-1.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 2 in Mean Pain Score for NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 2 in Mean Pain Score for NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.81" spread="2.039"/>
                    <measurement group_id="O2" value="-19.50" spread="2.501"/>
                    <measurement group_id="O3" value="-27.53" spread="2.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.078</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-5.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.226</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.93</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-13.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.249</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.01</ci_lower_limit>
            <ci_upper_limit>-6.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 3 in Mean Pain Score for NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 3 in Mean Pain Score for NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="226"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.64" spread="2.204"/>
                    <measurement group_id="O2" value="-26.10" spread="2.688"/>
                    <measurement group_id="O3" value="-40.13" spread="2.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-8.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.475</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.27</ci_lower_limit>
            <ci_upper_limit>-0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-22.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.514</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.38</ci_lower_limit>
            <ci_upper_limit>-14.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 4 in Mean Pain Score for NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 4 in Mean Pain Score for NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.94" spread="2.333"/>
                    <measurement group_id="O2" value="-32.05" spread="2.837"/>
                    <measurement group_id="O3" value="-48.35" spread="2.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-14.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.673</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.36</ci_lower_limit>
            <ci_upper_limit>-5.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-30.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.729</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.78</ci_lower_limit>
            <ci_upper_limit>-22.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 5 in Mean Pain Score for NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 5 in Mean Pain Score for NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.60" spread="2.371"/>
                    <measurement group_id="O2" value="-31.15" spread="2.888"/>
                    <measurement group_id="O3" value="-49.28" spread="2.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-11.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.736</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.94</ci_lower_limit>
            <ci_upper_limit>-3.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-29.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.788</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.19</ci_lower_limit>
            <ci_upper_limit>-21.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 6 in Mean Pain Score for NMPP</title>
        <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 6 in Mean Pain Score for NMPP</title>
          <description>The NMPP pain scale ranges from 0 (none) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.17" spread="2.418"/>
                    <measurement group_id="O2" value="-30.55" spread="2.939"/>
                    <measurement group_id="O3" value="-48.14" spread="3.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-12.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.805</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.92</ci_lower_limit>
            <ci_upper_limit>-3.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-29.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.868</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.66</ci_lower_limit>
            <ci_upper_limit>-21.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in Mean Pain Score of DYSP</title>
        <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in Mean Pain Score of DYSP</title>
          <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.032"/>
                    <measurement group_id="O2" value="-0.29" spread="0.040"/>
                    <measurement group_id="O3" value="-0.22" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.052</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.488</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 2 in Mean Pain Score of DYSP</title>
        <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 2 in Mean Pain Score of DYSP</title>
          <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.038"/>
                    <measurement group_id="O2" value="-0.33" spread="0.046"/>
                    <measurement group_id="O3" value="-0.38" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.252</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.060</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.061</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 4 in Mean Pain Score of DYSP</title>
        <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in Mean Pain Score of DYSP</title>
          <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.044"/>
                    <measurement group_id="O2" value="-0.45" spread="0.053"/>
                    <measurement group_id="O3" value="-0.61" spread="0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.069</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.071</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 5 in Mean Pain Score of DYSP</title>
        <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 5 in Mean Pain Score of DYSP</title>
          <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.047"/>
                    <measurement group_id="O2" value="-0.44" spread="0.056"/>
                    <measurement group_id="O3" value="-0.57" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.073</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.076</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in Mean Pain Score of DYSP</title>
        <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in Mean Pain Score of DYSP</title>
          <description>The DYSP pain scale ranged from 0 (absent) to 3 (severe).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases. Participants who responded &quot;not applicable&quot; for the entire time point and at Baseline are excluded from the analysis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.048"/>
                    <measurement group_id="O2" value="-0.41" spread="0.057"/>
                    <measurement group_id="O3" value="-0.60" spread="0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.118</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.074</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.078</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
        <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
          <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>pills</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.028"/>
                    <measurement group_id="O2" value="-0.25" spread="0.034"/>
                    <measurement group_id="O3" value="-0.32" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.313</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 2 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
        <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The modified intent-to-treat analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 2 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
          <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
          <population>The modified intent-to-treat analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>pills</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.029"/>
                    <measurement group_id="O2" value="-0.27" spread="0.036"/>
                    <measurement group_id="O3" value="-0.46" spread="0.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.519</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 4 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
        <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
          <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>pills</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.033"/>
                    <measurement group_id="O2" value="-0.39" spread="0.041"/>
                    <measurement group_id="O3" value="-0.57" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 5 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
        <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 5 in Analgesic Use Across Both Classes of Rescue Analgesics</title>
          <description>Permitted rescue medications included the nonsteroidal anti-inflammatory drug naproxen (500 mg), the narcotic analgesics 5 mg hydrocodone + 300 or 325 mg acetaminophen, and 30 mg codeine + 300 mg acetaminophen. Assessment was based on average pill counts.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>pills</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.034"/>
                    <measurement group_id="O2" value="-0.36" spread="0.041"/>
                    <measurement group_id="O3" value="-0.60" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.200</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.053</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.054</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Patient Global Impression of Change (PGIC) at Month 1</title>
        <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
        <time_frame>Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Response to Patient Global Impression of Change (PGIC) at Month 1</title>
          <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
                <count group_id="O2" value="234"/>
                <count group_id="O3" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="0.060"/>
                    <measurement group_id="O2" value="2.97" spread="0.073"/>
                    <measurement group_id="O3" value="2.76" spread="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.094</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.095</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to PGIC at Month 2</title>
        <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
        <time_frame>Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Response to PGIC at Month 2</title>
          <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="0.062"/>
                    <measurement group_id="O2" value="2.74" spread="0.076"/>
                    <measurement group_id="O3" value="2.11" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.098</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>-0.82</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to PGIC at Month 3</title>
        <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
        <time_frame>Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Response to PGIC at Month 3</title>
          <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="229"/>
                <count group_id="O3" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.14" spread="0.064"/>
                    <measurement group_id="O2" value="2.53" spread="0.079"/>
                    <measurement group_id="O3" value="2.01" spread="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.101</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.102</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.32</ci_lower_limit>
            <ci_upper_limit>-0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to PGIC at Month 4</title>
        <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
        <time_frame>Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Response to PGIC at Month 4</title>
          <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.16" spread="0.067"/>
                    <measurement group_id="O2" value="2.54" spread="0.082"/>
                    <measurement group_id="O3" value="1.91" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.106</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.47</ci_lower_limit>
            <ci_upper_limit>-1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to PGIC at Month 5</title>
        <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
        <time_frame>Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Response to PGIC at Month 5</title>
          <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="350"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.19" spread="0.070"/>
                    <measurement group_id="O2" value="2.50" spread="0.086"/>
                    <measurement group_id="O3" value="1.87" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.111</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.112</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.54</ci_lower_limit>
            <ci_upper_limit>-1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to PGIC at Month 6</title>
        <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
        <time_frame>Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Response to PGIC at Month 6</title>
          <description>The PGIC questionnaire is a self-reported 7-point scale rating a participant's overall impression of change from 1 = very much improved to 7 = very much worse. Participants evaluated the change in their endometriosis-associated pain since initiation of study drug.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="0.077"/>
                    <measurement group_id="O2" value="2.56" spread="0.094"/>
                    <measurement group_id="O3" value="1.92" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.122</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.96</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.123</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.59</ci_lower_limit>
            <ci_upper_limit>-1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in NRS Scores</title>
        <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in NRS Scores</title>
          <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="372"/>
                <count group_id="O2" value="248"/>
                <count group_id="O3" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.069"/>
                    <measurement group_id="O2" value="-1.00" spread="0.085"/>
                    <measurement group_id="O3" value="-1.12" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.109</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.110</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 2 in NRS Scores</title>
        <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 2 in NRS Scores</title>
          <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.086"/>
                    <measurement group_id="O2" value="-1.38" spread="0.106"/>
                    <measurement group_id="O3" value="-1.87" spread="0.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>-0.96</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.138</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>-0.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 4 in NRS Scores</title>
        <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in NRS Scores</title>
          <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="0.103"/>
                    <measurement group_id="O2" value="-1.95" spread="0.126"/>
                    <measurement group_id="O3" value="-2.76" spread="0.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.163</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.17</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.165</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.98</ci_lower_limit>
            <ci_upper_limit>-1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 5 in NRS Scores</title>
        <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 5 in NRS Scores</title>
          <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.106"/>
                    <measurement group_id="O2" value="-1.92" spread="0.129"/>
                    <measurement group_id="O3" value="-2.85" spread="0.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.167</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.170</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.99</ci_lower_limit>
            <ci_upper_limit>-1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in NRS Scores</title>
        <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in NRS Scores</title>
          <description>The NRS for overall endometriosis-associated pain ranges 0 (none) to 10 (worst pain ever).</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.15" spread="0.112"/>
                    <measurement group_id="O2" value="-1.80" spread="0.136"/>
                    <measurement group_id="O3" value="-2.75" spread="0.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.176</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.04</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>mixed-effects model</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.179</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.00</ci_lower_limit>
            <ci_upper_limit>-1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in the Pain Domain of the Endometriosis Health Profile-30 (EHP-30)</title>
        <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in the Pain Domain of the Endometriosis Health Profile-30 (EHP-30)</title>
          <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="345"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.47" spread="0.997"/>
                    <measurement group_id="O2" value="-20.76" spread="1.213"/>
                    <measurement group_id="O3" value="-24.23" spread="1.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-6.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.37</ci_lower_limit>
            <ci_upper_limit>-3.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-9.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.91</ci_lower_limit>
            <ci_upper_limit>-6.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in the Pain Domain of the EHP-30</title>
        <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in the Pain Domain of the EHP-30</title>
          <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.71" spread="1.101"/>
                    <measurement group_id="O2" value="-26.99" spread="1.321"/>
                    <measurement group_id="O3" value="-36.46" spread="1.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-9.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.66</ci_lower_limit>
            <ci_upper_limit>-5.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-18.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.77</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.22</ci_lower_limit>
            <ci_upper_limit>-15.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in the Pain Domain of the EHP-30</title>
        <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domian is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in the Pain Domain of the EHP-30</title>
          <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domian is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="177"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.42" spread="1.283"/>
                    <measurement group_id="O2" value="-27.99" spread="1.522"/>
                    <measurement group_id="O3" value="-40.52" spread="1.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-12.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.48</ci_lower_limit>
            <ci_upper_limit>-8.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-25.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.12</ci_lower_limit>
            <ci_upper_limit>-21.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in the Sexual Intercourse Domain of the EHP-30</title>
        <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domian is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in the Sexual Intercourse Domain of the EHP-30</title>
          <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domian is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.47" spread="1.239"/>
                    <measurement group_id="O2" value="-11.26" spread="1.488"/>
                    <measurement group_id="O3" value="-15.52" spread="1.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.685</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.59</ci_lower_limit>
            <ci_upper_limit>3.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-5.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.04</ci_lower_limit>
            <ci_upper_limit>-1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in the Sexual Intercourse Domain of the EHP-30</title>
        <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in the Sexual Intercourse Domain of the EHP-30</title>
          <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.57" spread="1.551"/>
                    <measurement group_id="O2" value="-17.32" spread="1.813"/>
                    <measurement group_id="O3" value="-26.44" spread="2.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-4.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.43</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-13.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.89</ci_lower_limit>
            <ci_upper_limit>-8.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in the Sexual Intercourse Domain of the EHP-30</title>
        <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domian is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in the Sexual Intercourse Domain of the EHP-30</title>
          <description>The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Each domian is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.56" spread="1.909"/>
                    <measurement group_id="O2" value="-16.27" spread="2.203"/>
                    <measurement group_id="O3" value="-29.07" spread="2.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.107</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-4.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.43</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-17.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.52</ci_lower_limit>
            <ci_upper_limit>-11.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in Health Related Productivity Questionnaire (HRPQ): Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in Health Related Productivity Questionnaire (HRPQ): Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="0.236"/>
                    <measurement group_id="O2" value="-1.20" spread="0.286"/>
                    <measurement group_id="O3" value="-2.49" spread="0.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.741</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.90</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="0.222"/>
                    <measurement group_id="O2" value="-1.77" spread="0.266"/>
                    <measurement group_id="O3" value="-2.56" spread="0.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.172</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.97</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.277"/>
                    <measurement group_id="O2" value="-1.92" spread="0.333"/>
                    <measurement group_id="O3" value="-2.65" spread="0.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-1.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.90</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.65</ci_lower_limit>
            <ci_upper_limit>-0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="0.284"/>
                    <measurement group_id="O2" value="-1.85" spread="0.334"/>
                    <measurement group_id="O3" value="-2.44" spread="0.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.080</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.77</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.63</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.25</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="0.258"/>
                    <measurement group_id="O2" value="-1.75" spread="0.308"/>
                    <measurement group_id="O3" value="-2.94" spread="0.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.106</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.67</ci_lower_limit>
            <ci_upper_limit>-1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.409"/>
                    <measurement group_id="O2" value="-1.02" spread="0.471"/>
                    <measurement group_id="O3" value="-2.48" spread="0.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.232</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.97</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.65</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.48</ci_lower_limit>
            <ci_upper_limit>-0.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="0.229"/>
                    <measurement group_id="O2" value="-2.19" spread="0.289"/>
                    <measurement group_id="O3" value="-2.89" spread="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.65</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.35</ci_lower_limit>
            <ci_upper_limit>-0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43" spread="0.295"/>
                    <measurement group_id="O2" value="-2.75" spread="0.360"/>
                    <measurement group_id="O3" value="-3.06" spread="0.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.24</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.56</ci_lower_limit>
            <ci_upper_limit>-0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="0.292"/>
                    <measurement group_id="O2" value="-3.00" spread="0.358"/>
                    <measurement group_id="O3" value="-3.47" spread="0.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.53</ci_lower_limit>
            <ci_upper_limit>-0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.02</ci_lower_limit>
            <ci_upper_limit>-1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="0.265"/>
                    <measurement group_id="O2" value="-2.59" spread="0.331"/>
                    <measurement group_id="O3" value="-3.61" spread="0.330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.05</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.06</ci_lower_limit>
            <ci_upper_limit>-1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.13" spread="0.250"/>
                    <measurement group_id="O2" value="-3.10" spread="0.302"/>
                    <measurement group_id="O3" value="-3.94" spread="0.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.97</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.74</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.81</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.58</ci_lower_limit>
            <ci_upper_limit>-1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="0.313"/>
                    <measurement group_id="O2" value="-2.73" spread="0.359"/>
                    <measurement group_id="O3" value="-3.94" spread="0.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.22</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.44</ci_lower_limit>
            <ci_upper_limit>-1.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.07" spread="0.555"/>
                    <measurement group_id="O2" value="-4.93" spread="0.668"/>
                    <measurement group_id="O3" value="-6.00" spread="0.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.326</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.57</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.67</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.42" spread="0.560"/>
                    <measurement group_id="O2" value="-6.83" spread="0.671"/>
                    <measurement group_id="O3" value="-8.94" spread="0.701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.107</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.13</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-3.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.90</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.28</ci_lower_limit>
            <ci_upper_limit>-1.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.23" spread="0.526"/>
                    <measurement group_id="O2" value="-7.24" spread="0.632"/>
                    <measurement group_id="O3" value="-9.16" spread="0.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.219</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.63</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.84</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.59</ci_lower_limit>
            <ci_upper_limit>-1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.81" spread="0.465"/>
                    <measurement group_id="O2" value="-8.41" spread="0.546"/>
                    <measurement group_id="O3" value="-10.70" spread="0.573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.01</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-3.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.34</ci_lower_limit>
            <ci_upper_limit>-2.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.80" spread="0.488"/>
                    <measurement group_id="O2" value="-8.31" spread="0.577"/>
                    <measurement group_id="O3" value="-10.93" spread="0.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.502</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.76</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.00</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-3.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.70</ci_lower_limit>
            <ci_upper_limit>-1.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="118"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.75" spread="0.554"/>
                    <measurement group_id="O2" value="-8.11" spread="0.637"/>
                    <measurement group_id="O3" value="-11.21" spread="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.02</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-4.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.19</ci_lower_limit>
            <ci_upper_limit>-2.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.224"/>
                    <measurement group_id="O2" value="-1.64" spread="0.281"/>
                    <measurement group_id="O3" value="-1.51" spread="0.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.90</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.76</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
                <count group_id="O2" value="190"/>
                <count group_id="O3" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="0.238"/>
                    <measurement group_id="O2" value="-1.93" spread="0.291"/>
                    <measurement group_id="O3" value="-2.23" spread="0.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>mixed-effects model</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.81</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.35" spread="0.210"/>
                    <measurement group_id="O2" value="-1.89" spread="0.256"/>
                    <measurement group_id="O3" value="-2.33" spread="0.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.103</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.64</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.51" spread="0.224"/>
                    <measurement group_id="O2" value="-1.81" spread="0.280"/>
                    <measurement group_id="O3" value="-2.55" spread="0.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.390</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.75</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="172"/>
                <count group_id="O3" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" spread="0.169"/>
                    <measurement group_id="O2" value="-1.86" spread="0.205"/>
                    <measurement group_id="O3" value="-2.71" spread="0.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.460</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.57</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to presenteeism [working while sick]) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="0.232"/>
                    <measurement group_id="O2" value="-2.07" spread="0.265"/>
                    <measurement group_id="O3" value="-2.78" spread="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.095</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean of Difference</param_type>
            <param_value>-0.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.28</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.01</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.46" spread="0.615"/>
                    <measurement group_id="O2" value="-6.17" spread="0.745"/>
                    <measurement group_id="O3" value="-8.69" spread="0.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.462</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.61</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-3.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.16</ci_lower_limit>
            <ci_upper_limit>-1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 2 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 2 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="160"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.70" spread="0.621"/>
                    <measurement group_id="O2" value="-8.72" spread="0.746"/>
                    <measurement group_id="O3" value="-11.56" spread="0.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.93</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-4.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.00</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.82</ci_lower_limit>
            <ci_upper_limit>-2.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.00" spread="0.654"/>
                    <measurement group_id="O2" value="-9.20" spread="0.787"/>
                    <measurement group_id="O3" value="-11.90" spread="0.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.21</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-4.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.95</ci_lower_limit>
            <ci_upper_limit>-2.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 4 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.84" spread="0.605"/>
                    <measurement group_id="O2" value="-10.26" spread="0.712"/>
                    <measurement group_id="O3" value="-13.09" spread="0.747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.26</ci_lower_limit>
            <ci_upper_limit>-0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-5.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.96</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.14</ci_lower_limit>
            <ci_upper_limit>-3.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 5 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 5 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.87" spread="0.604"/>
                    <measurement group_id="O2" value="-10.04" spread="0.719"/>
                    <measurement group_id="O3" value="-14.00" spread="0.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.215</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.94</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.02</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-5.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.06</ci_lower_limit>
            <ci_upper_limit>-3.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the workplace due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.88" spread="0.761"/>
                    <measurement group_id="O2" value="-9.14" spread="0.874"/>
                    <measurement group_id="O3" value="-13.67" spread="0.936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.53</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-6.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.17</ci_lower_limit>
            <ci_upper_limit>-4.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 1 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 1 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 1 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="0.352"/>
                    <measurement group_id="O2" value="-3.88" spread="0.445"/>
                    <measurement group_id="O3" value="-4.36" spread="0.443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.24</ci_lower_limit>
            <ci_upper_limit>-1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.71</ci_lower_limit>
            <ci_upper_limit>-1.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 2 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 2 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 2 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.60" spread="0.423"/>
                    <measurement group_id="O2" value="-4.69" spread="0.517"/>
                    <measurement group_id="O3" value="-5.25" spread="0.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.40</ci_lower_limit>
            <ci_upper_limit>-0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.98</ci_lower_limit>
            <ci_upper_limit>-1.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 3 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 3 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 3 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.73" spread="0.394"/>
                    <measurement group_id="O2" value="-4.90" spread="0.483"/>
                    <measurement group_id="O3" value="-5.73" spread="0.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.39</ci_lower_limit>
            <ci_upper_limit>-0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-3.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.23</ci_lower_limit>
            <ci_upper_limit>-1.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 4 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 4 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 4 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" spread="0.403"/>
                    <measurement group_id="O2" value="-4.43" spread="0.502"/>
                    <measurement group_id="O3" value="-6.13" spread="0.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.80</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-3.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.50</ci_lower_limit>
            <ci_upper_limit>-1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 5 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 5 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 5 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.80" spread="0.349"/>
                    <measurement group_id="O2" value="-4.94" spread="0.423"/>
                    <measurement group_id="O3" value="-6.62" spread="0.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.22</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.91</ci_lower_limit>
            <ci_upper_limit>-1.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
        <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
        <time_frame>Baseline, Month 6 of Treatment Period</time_frame>
        <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 6 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household</title>
          <description>The HRPQ consists of questions measuring the impact of endometriosis-associated pain and its treatment on work productivity (number of work hours lost from the household due to absenteeism and presenteeism) in the 7 days prior to survey administration.</description>
          <population>The mITT analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Observed cases.</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.94" spread="0.433"/>
                    <measurement group_id="O2" value="-4.78" spread="0.496"/>
                    <measurement group_id="O3" value="-6.69" spread="0.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.66</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.13</ci_lower_limit>
            <ci_upper_limit>-0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-3.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.06</ci_lower_limit>
            <ci_upper_limit>-2.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Endometriosis-Related Non-Study Health Visits During the Treatment Period</title>
        <time_frame>Up to Month 6 of Treatment Period</time_frame>
        <population>The modified intent-to-treat analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Endometriosis-Related Non-Study Health Visits During the Treatment Period</title>
          <population>The modified intent-to-treat analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="249"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Hospitalization</title>
        <time_frame>Up to Month 6 of Treatment Period</time_frame>
        <population>The modified intent-to-treat analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Includes participants who were hospitalized during the Treatment Period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Hospitalization</title>
          <population>The modified intent-to-treat analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug. Includes participants who were hospitalized during the Treatment Period.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.45"/>
                    <measurement group_id="O2" value="2.0" spread="1.00"/>
                    <measurement group_id="O3" value="2.0" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Emergency Room/Outpatient Procedures During the Treatment Period, by Type</title>
        <time_frame>Up to Month 6 of Treatment Period</time_frame>
        <population>The modified intent-to-treat analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo BID for the 6-month Treatment Period</description>
          </group>
          <group group_id="O2">
            <title>Elagolix 150 mg QD</title>
            <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
          </group>
          <group group_id="O3">
            <title>Elagolix 200 mg BID</title>
            <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Emergency Room/Outpatient Procedures During the Treatment Period, by Type</title>
          <population>The modified intent-to-treat analysis set included all randomized participants who took at least 1 dose of randomized, double-blind study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="249"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Categories</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Hysterectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiography</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthroscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biopsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood Draw</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Consultation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CT Scan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diagnostic Laparoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electrocardiogram</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endometrial Ablation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histological Exam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intrauterine Insemination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In Vitro Fertilization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laparoscopic Hysterectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laparotomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnetic Resonance Imaging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oophorectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic Exam</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Examination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery for Adhesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Therapeutic Laparoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ultrasound</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal Hysterectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>X-Ray</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Not Specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study treatment through 6 months of treatment plus up to 12 months of follow-up.</time_frame>
      <desc>Adverse events (AEs) are defined as treatment-emergent if they began on or after the date of the first dose of study drug through up to 30 days after the last dose of study drug for participants who did not enroll in the separate extension study (Study M12-667, NCT01760954). For participants who enrolled in the separate extension study, treatment-emergent AEs are those that began on or after the first dose of study drug until the day prior to the first dose date in the extension study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo BID for the 6-month Treatment Period</description>
        </group>
        <group group_id="E2">
          <title>Elagolix 150 MG QD</title>
          <description>Elagolix 150 mg QD for the 6-month Treatment Period</description>
        </group>
        <group group_id="E3">
          <title>Elagolix 200 MG BID</title>
          <description>Elagolix 200 mg BID for the 6-month Treatment Period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>MENINGITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>SYNOVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ECTOPIC PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>URETERIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ENDOMETRIOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST RUPTURED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>PELVIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>VICTIM OF SEXUAL ABUSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="159" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>AMENORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="248"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="249"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="248"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

